Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04048278 · ClinicalTrials.gov registry record · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
A Early Phase 1 study of Pancreatic Cancer, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT04048278 is a Early Phase 1 study of Pancreatic Cancer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 46 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04048278, a Early Phase 1 study of Pancreatic Cancer, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.
Conditions Studied
Interventions
- DRUG Lidocaine Hydrochloride
- DRUG Saline Solution for Injection
Study Locations (1)
Illinois
- University of Illnois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2026-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04048278
The ClinicalTrials.gov registry entry for NCT04048278 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (88% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine Hydrochloride is the first listed.
NCT04048278 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04048278 about?
NCT04048278 is a clinical study titled "Lidocaine Infusion in Pancreatic Cancer". This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will ...
What is the current status of trial NCT04048278?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2018-11-08. Estimated completion is 2026-01-01.
What conditions does trial NCT04048278 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT04048278?
The interventions under investigation include: Lidocaine Hydrochloride (DRUG), Saline Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT04048278?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04048278 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.